gimsilumab
mAbexperimentalCOVID-19
Gimsilumab (MORAb-022) (INN) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. — Wikipedia
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01357759)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGimsilumab ↗
- ChEMBLCHEMBL2109430 ↗
Also known as
- morab-022
- morab-022
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04351243 | Phase 2 | Apr 30, 2020 | Kinevant Sciences GmbH |
| NCT04205851 | Phase 1 | Nov 12, 2019 | Kinevant Sciences GmbH |
| NCT01357759 | Phase 1 | May 1, 2013 | Altoona Center for Clinical Research, AXIS Clinicals Limited, Lynn Health Science Institute, Morphotek, Seaview Jacksonville, LLC |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kinevant Sciences GmbH | For profit | 2 | 2 | 2 | 2019 |
| Altoona Center for Clinical Research | For profit | 1 | 0 | 1 | 2013 |
| AXIS Clinicals Limited | For profit | 1 | 0 | 1 | 2013 |
| Lynn Health Science Institute | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Morphotek | For profit | 1 | 1 | 1 | 2013 |
| Seaview Jacksonville, LLC | Academic/Hospital | 1 | 0 | 1 | 2013 |
6 organizations
Page 1 / 1